Paris (France), April 23, 2021 – 7.00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the publication of the Company’s 2020 annual financial report.

The 2020 annual financial report is available to the public on the Company’s website.

• Download the full press release